This move by the Commission was expected, given the announcements made by the Government of the Republic of Serbia last year.
Sector inquiries are conducted if certain circumstances indicate potential antitrust violations, or the possibility of restricting, distorting, or preventing competition, in order for the Commission to further examine the state of competition in a particular industry.
The subject of the above-mentioned inquiry is the market for medicines used in human medicine, with a special focus on medicines that are issued at the expense of the mandatory health insurance fund.
More information provided by JPM Partner Nikola Poznanović and Senior Associate Katarina Rosić can be found here.
